Assessment of cardiac inflammation and remodeling during the development of streptozotocin-induced diabetic cardiomyopathy in vivo: a time course analysis

Int J Mol Med. 2013 Jul;32(1):158-64. doi: 10.3892/ijmm.2013.1368. Epub 2013 May 2.

Abstract

In this study, we examined cardiac inflammation, fibrosis and left ventricular (LV) function during the development of streptozotocin (STZ)-induced diabetic cardiomyopathy using an animal model of diabetes mellitus (DM). Diabetes was induced in 22 Sprague‑Dawley rats by an intraperitoneal single injection of STZ (70 mg/kg). Non-diabetic animals served as the controls (n=6). LV function was documented using the conductance catheter technique 2 and 6 weeks after the induction of diabetes. Cardiac tissue was analyzed for cardiac immune cell infiltration, oxidative stress and remodeling in rats with STZ-induced diabetes at 2 different time points by immunohistochemistry. Cardiac function was significantly impaired in the diabetic animals. After 2 weeks, the induction of diabetes resulted in impaired cardiac function indexed by a decrease in systolic and diastolic LV function. This impairment of LV performance continued for up to 6 weeks after the STZ injection. This was associated with an increase in cardiac CD3+ and CD8a+ immune cell invasion and fibrosis, indexed by an increase in collagen content (p<0.05). Furthermore, oxidative stress response and matrix remodeling were increased after 2 weeks and this continued for up to 6 weeks after the induction of diabetes. In conclusion, cardiac dysfunction is associated with cardiac inflammation and adverse remodeling in experimental diabetic cardiomyopathy. Our results suggest that the model of STZ-induced diabetic cardiomyopathy is a robust model for investigating cardiac immune response and LV remodeling processes under diabetic conditions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / adverse effects*
  • Diabetes Mellitus, Experimental
  • Diabetic Cardiomyopathies / chemically induced*
  • Diabetic Cardiomyopathies / immunology
  • Diabetic Cardiomyopathies / pathology*
  • Diabetic Cardiomyopathies / physiopathology
  • Extracellular Matrix / metabolism
  • Fibrosis
  • Hemodynamics
  • Inflammation / immunology
  • Inflammation / pathology*
  • Oxidative Stress
  • Rats
  • Streptozocin / adverse effects*
  • Time Factors
  • Ventricular Remodeling*

Substances

  • Antibiotics, Antineoplastic
  • Streptozocin